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Objective: This study aimed to evaluate the inﬂuence of fetal hemoglobin (Hb F) on hemolysis
biomarkers in sickle cell anemia patients.
Methods: Fifty adult sickle cell anemia patients were included in the study. All patients were
taking hydroxyurea for at least six months and were followed at the outpatient clinic of
a  hospital in Fortaleza, Ceará, Brazil. The control group consisted of 20 hemoglobin AA
individuals. The reticulocyte count was performed by an automated methodology, lac-
tate dehydrogenase and uric acid were measured by spectrophotometry and arginase I
by  enzyme-linked immunosorbent assay (ELISA). The presence of Hb S was detected by
high-performance liquid chromatography. The level of signiﬁcance was set for a p-value
<0.05.
Results: A signiﬁcant increase was observed in the reticulocyte count and lactate dehy-
drogenase, uric acid and arginase I levels in sickle cell anemia patients compared to the
control group (p-value <0.05). Patients having Hb F levels greater than 10% showed a signiﬁ-
cant decrease in the reticulocyte count, arginase I and lactate dehydrogenase. A signiﬁcant
decrease was observed in arginase I levels in patients taking hydroxyurea at a dose greater
than 20 mg/kg/day.
Conclusion: The results of this study show that sickle cell anemia patients have increases
in  the hemolysis biomarkers, lactate dehydrogenase, reticulocyte count, arginase I, uric
acid and increases in Hb F can reduce the reticulocyte count and arginase I and lactate
dehydrogenase levels.©  2015 Associac¸a˜o Bra
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ulocyte count, LDH, uric acid and arginase I were observed
in patients with SCA compared to the control group (p-value168  rev bras hematol hem
Introduction
Sickle cell anemia (SCA) is an hemolytic anemia characterized
by structural changes in the -globin chain, leading to the syn-
thesis of an abnormal hemoglobin (Hb) in homozygous (Hb
SS).1
The primary event liable for any complications in SCA is
the polymerization of Hb S, which culminates in hemolysis
and vaso-occlusive events. These in turn trigger other events
such as an inﬂammatory process, increased oxidative stress,
endothelial dysfunction and decreased availability of nitric
oxide (NO).2
Lactate dehydrogenase (LDH) is a marker of intravascular
hemolysis and elevations in its plasma concentration are asso-
ciated with the clinical phenotype of pulmonary hypertension,
priapism and leg ulcers in SCA.3 Studies have demonstrated
that LDH may be a useful marker of disease complications
related to hemolysis.2,4
Hyperuricemia occurs only in SCA patients who develop
abnormal renal tubular function, with decreased uric acid
clearance secondary to decreased urate excretion.5
Arginase is the enzyme that converts L-arginine to
ornithine and urea. During the hemolysis process, this
enzyme is released from red blood cells, contributing
to the consumption of L-arginine and decreasing NO
concentrations.6,7
There are two distinct isoforms of arginase (I and II),
which are encoded by different genes and differ in molecular
and immunological properties, tissue distribution, subcellular
localization and regulation of expression.8 Arginase I is pri-
marily expressed in the liver and red blood cells, whereas the
expression of arginase II (mitochondrial enzyme) is diffused
in various tissues such as the brain, bone marrow, kidney,
small intestine and mammary  glands.9 During the process
of hemolysis, NO reacts with Hb to form methemoglobin and
nitrate.
Arginase is an enzyme abundant in reticulocytes which
predominate in patients with chronic hemolytic anemia, in
particular SCA as there is a rapid turnover of red blood cells.
Patients who  have low arginine levels are more  likely to
develop pulmonary hypertension, stroke, priapism and leg
ulcers, and consequently increased mortality.2,7 Studies have
shown a positive association of arginase I with hemolysis
markers such as total bilirubin, indirect bilirubin and aspartate
aminotransferase.10,11
Fetal hemoglobin (Hb F) is the most powerful modulator
of the clinical and hematologic features of SCA inﬂuencing
both clinical and laboratory features. The pathophysiol-
ogy of this disease is dependent on the polymerization of
deoxy-sickle Hb; the Hb F concentration reduces this pro-
cess, thereby reducing hemolysis and vaso-occlusive events.
The use of hydroxyurea may contribute to increased Hb F
production, however, not all patients respond well to this
drug.12–15
Thus, the present study aims to evaluate the impact of
the Hb F on hemolysis biomarkers in adult patients with
SCA. 2 0 1 5;3  7(3):167–171
Methods
Subjects  and  samples
This was a cross-sectional and analytical study of ﬁfty adult
SCA patients under outpatient treatment at the University
Hospital of the Universidade Federal do Ceará (UFC) in For-
taleza, Ceará, Brazil from March 2012 to March 2013. All
patients signed informed consent forms according to the
research protocol approved by the Ethics Committee of the
UFC. Eligibility criteria included adult patients with molecular
diagnostics of SCA taking hydroxyurea at a dose of between
0.5 and 1.5 g/day for at least six months without recent
blood transfusions. Transfusions were documented by the
absence of Hb A measured by high-performance liquid chro-
matography (HPLC) (Ultra Resolution System, Trinity Biotech),
according to the criteria described by Ballas et al.16 A control
group was composed by twenty blood donors (Hb AA).
Analysis  of  biomarkers
A venous blood sample (10 mL)  was collected in a tube contain-
ing the ethylenediaminetetraacetic acid (EDTA) anticoagulant
to manually perform a reticulocyte count and to measure the
percentage of Hb F by HPLC analysis. Moreover a 6-mL venous
blood sample was collected in a tube with separator gel but
without anticoagulant to measure serum LDH, uric acid and
arginase I. LDH and uric acid were measured by kinetic analy-
sis using the Labtest® kit. The serum concentration of arginase
I was determined according to the enzyme-linked immunosor-
bent assay (ELISA) kit for human arginase protocol (USCNK Life
Science Inc.). The kit is a sandwich enzyme immunoassay for
in vitro quantitative measurement of serum arginase I.
Statistical  analysis
Statistical analysis was performed using GraphPad Prism
5.0 (USA). Initially, data normality was analyzed using
the Kolmogorov–Smirnov test. The unpaired t-test and
Mann–Whitney test were used to compare two  numerical vari-
ables. A multiple comparison of means was performed using
the analysis of variance (ANOVA) test (Bartlett’s test for equal
variances) followed by Newman–Keuls post-test to identify
which groups were different. The Spearman test was used to
correlate the arginase I with Hb F concentration, reticulocyte
count, LDH and uric acid levels. All results were expressed as
means ± standard error of the mean (SEM). The level of signif-
icance for all analyses was set for a p-value <0.05.
Results
The demographic and hematological characteristics of the
patients are shown in Table 1. Signiﬁcant increases in the retic-<0.05) (Table 2). Patients with Hb F concentration lower than
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Table 1 – Demographic and hematologic parameters of
sickle cell anemia patients (n = 50) and control group
(n = 20).
Patients (n = 50) Control (n = 20)
Gender (F/M) 28/22 14/6
Age 37.78 (20–63) 27.67 (20–55)
Hemoglobin (g/dL) 8.596 ± 0.2093 12.34 ± 0.5
Hematocrit (%) 24.93 ± 0.5791 39 ± 0.6
MCV (fL) 98.84 ± 1.515 94.4 ± 1.5
MCH (pg) 34.50 ± 0.6112 33.4 ± 0.8
MCHC (%) 34.41 ± 0.1868 32.5 ± 0.5
Leucocytes (×109/L) 13.7 ± 2.7 6.3 ± 1.6
Platelets (×109/L) 381.8 ± 24.5 390.2 ± 25.7
Hb F (%) 12.68 ± 1.162 –
Hb S (%) 80.93 ± 1.006 –
MCV: Mean corpuscular volume; MCH: Mean corpuscular
hemoglobin; Hb F: Fetal hemoglobin; Hb S: Sickle hemoglobin.
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merization, contributing to an improvement in hemolysis andData are expressed in mean ± standard error of the mean (SEM).
r equal to 10% showed a signiﬁcant increase in the reticu-
ocyte count, and arginase I and LDH levels (Figure 1). There
as no correlation between the Hb F and uric acid. Patients
n low doses of hydroxyurea (<20 mg/kg/day) had a signiﬁcant
ncrease in the arginase I levels (Figure 2). Moreover, there was
o signiﬁcant relationship between hydroxyurea doses and Hb
, LDH, and uric acid levels or the reticulocyte count.
iscussion
CA is characterized by the presence of Hb S in homozygous
nd is associated with a heterogeneous clinical presentation,
ncluding severe hemolytic anemia, painful crises, and vaso-
cclusive events. It is associated with high morbidity and
ortality, mainly due to infections, and so studies that might
stablish prognostic markers for the most severe clinical man-
festations of the disease are necessary.17
A signiﬁcant increase in the reticulocyte count was
bserved in SCA patients compared to control individuals.
eticulocytosis is a response to the hemolytic process. Cortel-
azzi et al.18 demonstrated a signiﬁcant difference in the
eticulocyte count in adult patients with SCA compared to control group (Hb AA). Some authors have attributed the
ncreased reticulocyte count to increased expansion of the
rythroid lineage.2,19
Table 2 – Comparative analysis of the hemolysis parameters in
(n = 20).
Parameters n Patients
Mean ± SEM
Reticulocytes (%) 50 13.85 ± 0.89 
LDH (U/L) 50  636.20 ± 62.64 
Uric acid (mg/dL) 50 5.46 ± 0.28 
Arginase I (ng/mL) 50 71.87 ± 4.44 
LDH: Lactate dehydrogenase.
Data are expressed as means ± standard error of the mean (SEM) and an
differences are deﬁned as a p-value <0.05. 1 5;3  7(3):167–171 169
In the present study there was a signiﬁcant increase of
serum LDH in patients with SCA compared to the control
group. These results are in agreement with the study of Elias
et al.20 who found a signiﬁcant increase of LDH compared to
a control group in the same study population at steady state.
Stojanovic et al.21 found an elevation in serum LDH  levels in
patients with SCA in both steady state and in crises. Taylor
et al.22 suggest using the determination of LDH in patients
with SCA at baseline as a predictive marker of increased risk
of mortality due to the infrequency of vaso-occlusive events.
In a prospective study, Najim and Hassan23 evaluated LDH as
a marker of vaso-occlusion in SCA children and adolescents
during episodes. LDH is an enzyme associated with hyper-
hemolysis; the authors concluded that LDH is an efﬁcient
biochemical marker of the severity of pain during vaso-
occlusive episodes.2,19,22 The SCA patients in this study with
high Hb F concentrations (>10%) had lower LDH levels, which
shows the important role of Hb F in the hemolysis process.
A signiﬁcant increase in uric acid has been reported in SCA
patients compared to control groups. Cerqueira et al.11 showed
a positive correlation between uric acid and biomarkers of
hemolysis by measuring indirect and total bilirubin levels in
SCA patients. However, in the present study no relationship
was observed between uric acid levels and other hemolysis
markers or Hb F levels. The study of Al-Naama et al.24 showed
that uric acid levels were higher in SCA patients than in a con-
trol group. These authors attributed the elevation of uric acid
to increased bone marrow activity and renewal of nucleic acids
that can occur during the hemolysis process.
The results of this study demonstrate an increase in the
arginase I levels in SCA patients compared to a control group.
These results corroborate a study by Vilas-Boas et al.25 who
reported a signiﬁcant difference in serum arginase in patients
with SCA compared to control individuals. The data of the
study demonstrate that arginase I is a marker of hemolysis
which increases in SCA at steady state and can be used in
practice as a modulator of hemolysis.
No correlation was conﬁrmed between the Hb F level and
the hemolysis parameters studied, although signiﬁcant dif-
ferences in the levels of arginase I, LDH and reticulocytes
were observed between patients with low and high Hb F
concentrations. This Hb is the main inhibitor of Hb S poly-vaso-occlusive events. By inhibiting the tendency that Hb S is
polymerized, Hb F prevents the cell damage caused thereby
reducing clinical complications in SCA patients.12
 sickle cell anemia patients (n = 50) and the control group
n  Control
Mean ± SEM
p-value
20 0.94 ± 0.09 <0.0001
20 310.60 ± 8.39 0.0064
20 3.61 ± 0.17 <0.0001
20 8.61 ± 0.36 <0.0001
alyzed by the Mann–Whitney test and Unpaired t test; signiﬁcant
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Figure 1 – Comparison of hemolysis biomarkers levels according to HbF concentration. (A) Reticulocytes; (B) Uric Acid; (C)
Lactate dehydrogenase (LDH); (D) Arginase I. Results are expressed as means ± standard error of the mean (SEM) and
analyzed using the unpaired t-test and Mann–Whitney test.
Concerning to the use of hydroxyurea, a signiﬁcant dif-
ference was observed in the levels of arginase I in patients
who  used lower doses (<20 mg/kg/day) compared to those
on higher doses of hydroxyurea (≥20 mg/kg/day) however,
there were no signiﬁcant differences in LDH, uric acid and
reticulocytes. Although hydroxyurea can be used in SCA
as it can increase the concentration of Hb F, some patients
may not respond well to medication, with many  factors
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Figure 2 – Comparison of arginase I levels according to HU
dosage. Results are expressed in mean ± standard error of
mean (SEM) and analyzed by Unpaired t test.
rinvolved, ranging from genetic polymorphisms to changes in
the absorption and metabolism of the drug.13,26,27
The current study did not include patients not taking
hydroxyurea, as more  than 70% of the patients of the insti-
tutions of this study have clinical indications and are thus
treated using hydroxyurea. Further studies should be per-
formed to consolidate the results on hemolytic biomarkers as
a prognostic parameter in SCA. Our ﬁndings suggest that the
Hb F concentration can interfere in hemolysis. However, other
mechanisms such as genetic factors and the use of hydrox-
yurea may also affect these parameters.
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